Alistair Stewart currently serves as the Senior Director of Chemical Development at GSK, where he leverages his extensive experience in drug development to drive innovation and efficiency within the Chemistry, Manufacturing, and Controls (CMC) sector. With a robust background spanning Research and Development (R&D), pre-clinical...
Alistair Stewart currently serves as the Senior Director of Chemical Development at GSK, where he leverages his extensive experience in drug development to drive innovation and efficiency within the Chemistry, Manufacturing, and Controls (CMC) sector. With a robust background spanning Research and Development (R&D), pre-clinical studies, and manufacturing operations, Alistair plays a pivotal role in overseeing both non-GMP and GMP projects, ensuring that they meet stringent regulatory standards while optimizing performance.
One of Alistair's key projects involves the strategic lifecycle management of niraparib, a critical asset in GSK's oncology portfolio. His responsibilities include the seamless transfer of technical knowledge related to drug substance manufacturing, which is essential for maintaining the integrity and quality of the product throughout its lifecycle. By collaborating closely with cross-functional teams, Alistair provides invaluable insights into API process improvements aimed at enhancing safety, reducing costs, increasing throughput, and minimizing cycle times.
Alistair's expertise in medicinal chemistry, technology transfer, and analytical chemistry positions him as a thought leader in the biopharmaceutical industry. His proficiency in HPLC and clinical trials further underscores his commitment to advancing drug development processes. As he continues to navigate the complexities of CMC, Alistair remains dedicated to fostering innovation and ensuring that GSK remains at the forefront of pharmaceutical excellence. His strategic vision and hands-on approach not only drive project success but also contribute to the broader mission of delivering transformative therapies to patients worldwide.
